Srb Corp Biogen Inc. Transaction History

Srb Corp

$1.78 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $390,304 - $451,009	1,418 New	1,418 $403,000
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $367,805 - $446,891	1,457 New	1,457 $404,000
Q2 2022 Aug 12, 2022	BUY	$187.54 - $223.02 $436,780 - $519,413	2,329 Added 43.84%	7,641 $1.56 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $101,435 - $130,359	453 Added 9.32%	5,312 $1.27 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $1.38 Million - $1.79 Million	4,859 New	4,859 $1.38 Million
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $477,245 - $718,372	-2,020 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $114,645 - $132,372	433 Added 27.28%	2,020 $573,000
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $426,664 - $541,230	1,587 New	1,587 $502,000
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $431,097 - $595,673	-1,959 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $32,181 - $36,094	-148 Reduced 7.02%	1,959 $457,000
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $23,902 - $26,347	-109 Reduced 4.92%	2,107 $492,000
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $94,485 - $147,786	436 Added 24.49%	2,216 $524,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $495,730 - $627,895	1,780 New	1,780 $536,000
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $498,086 - $651,359	-1,697 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $253,399 - $301,999	984 Added 138.01%	1,697 $492,000
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $23,671 - $33,479	91 Added 14.63%	713 $195,000
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $29,520 - $34,617	-105 Reduced 14.44%	622 $195,000
Q2 2017 Aug 14, 2017	BUY	N/A	727	727 $197,000

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Srb Corp, based on Form 13F filings with the SEC.

News

Stay updated on Srb Corp with notifications on news.

Account